Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Heidi Trinkman"'
Autor:
Angela Liu, Paige Vicenzi, Ishna Sharma, Kaci Orr, Christa Teller, Micha Koentz, Heidi Trinkman, Kelly Vallance, Anish Ray
Publikováno v:
Hematology Reports, Vol 15, Iss 2, Pp 244-255 (2023)
The application of molecular tumor profiles in clinical decision making remains a challenge. To aid in the interpretation of complex biomarkers, molecular tumor boards (MTBs) have been established worldwide. In the present study, we show that a multi
Externí odkaz:
https://doaj.org/article/a6931db0fe19455eb970c982e6234b49
Publikováno v:
Journal of Pediatric Hematology/Oncology. 45:e479-e482
Autor:
Shelley Watts, Maranda Diaz, Christa Teller, Tyler Hamby, Ricardo Guirola, Maria Perez, Gretchen Eames, Richard Howrey, Ana Rios, Heidi Trinkman, Anish Ray
Publikováno v:
Journal of Pediatric Hematology/Oncology. 45:e328-e333
Autor:
Liu, Angela, Vicenzi, Paige, Sharma, Ishna, Orr, Kaci, Teller, Christa, Koentz, Micha, Heidi Trinkman, Vallance, Kelly, Ray, Anish
Publikováno v:
Hematology Reports; Jun2023, Vol. 15 Issue 2, p244-255, 12p
Background Palonosetron is a serotonin-3 (5-HT3) receptor antagonist indicated in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric and adult patients. Traditional dosing for palonosetron in the pediatric population has b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af58e839167b542def60b9e1d54af3a0
https://doi.org/10.22541/au.162395520.08447874/v1
https://doi.org/10.22541/au.162395520.08447874/v1
Autor:
Heidi Trinkman, Matthew Carroll, Mackenzie Creamer, Lorrainea Williams, Artee Gandhi, Tyler Hamby
Publikováno v:
Journal of pediatric surgery. 56(8)
This study aimed to evaluate the impact of a Pediatric Acute Pain Guideline on postsurgical pain scores, opioid exposure, and discharge opioid prescribing habits in postappendectomy patients.This was a retrospective single-center quality improvement
Publikováno v:
Journal of pediatric hematology/oncology. 37(2)
Therapy with the tyrosine kinase inhibitor imatinib mesylate has become standard initial treatment for adult and pediatric patients with chronic myelogenous leukemia. Long-term follow-up data are now available in the adult population, and the toxicit